ImmunoGen, Inc. (NASDAQ:IMGN) could be one of the best stocks that investors may want to consider for their portfolio today as the company shares are trading 3.53% or 0.115 points up from last closing price of $3.26, reaching $3.375 at last check. Any clue why there is so much of action in the IMGN stock? The share price has risen in 2 of the last 5 days and is up 13.59% over the past week. It will be exciting to see whether the stock manages to continue increasing or take a minor break for the next few days. The move came on weak volume too with far less shares changing hands than in a normal session. Trading activity as of this writing weakened by -698,944 shares, and in total 724756 shares valued at $2.446 million were seen changing hands compared with 1.424 million shares valued at $4.641 million recorded at the previous session. You should take into consideration that a falling volume on higher prices causes divergence and may be an early warning about possible changes in IMGN stock for the next couple of days.
ImmunoGen, Inc. (IMGN) shares have notched a 3-month gain of about 13.59%, but has still tumbled -32.08% year to date. By comparison, the stock sank -40.83% over the past 12 months, while it jumped 42.36% over the 1 month. The company’s market cap is around $382.53M, with its short interest ratio standing at 4.36%.
In the current trading session for IMGN, the stock witnessed two major price actions, it rose to a high of $3.37 and was down as much as $3.21 at one point. The high recorded is very low when compared to their 52-week high which is $1.76. The 52-week high is now at -47.96 distance from current price. Their recent low of $6.47 represents a 91.47% recovery. This data is quite important for investors who look to benefit from the recent rise of the company’s stock. The price target currently for IMGN is $4.67, this is below the recent high that the stock attained. Taking a look at the overall sentimental views of financial analysts, the trading pattern of this stock recently is very clear.
The stock of ImmunoGen, Inc. earned $-1.19 per share in the trailing 12 months and has a P/E ratio of -2.84. You can compare it with that of similar companies in its industry to get a sense of whether the stock you’re looking to purchase is overvalued or undervalued. Its current price to earnings ratio is lower than the ones recorded by the industry which is 21.38 and lower compared to the sector’s average of 31.63. When the P/E ratio is low let’s say below 1.0, then the stock price is considered a good value. IMGN also has P/S multiple of 8.17. This is greater versus the 12 month P/S ratios of other companies in the same indutry. The peer average price to sales ratio is 2.59x.
IMGN‘s last price was up 17.42% as compared to the average trading price of 50 days recorded at $2.87 while enlarging the period to 200 trading days, the average closing price was $2.77. At present, there are 117.34 million in the total number of common shares owned by the public and among those shares have been available to trade. The percentage of shares being held by the company management was 0.6% while institutions stake was 67.4%. The company has generated negative returns on equity over the last 12 months (0%). It managed to keep its gross profit margin at 0% over the past 12 months.
When assessing the full upside of the IMGN stock, there is another set of technicals that should be looked into and considered. Its 23.64% gain from moving average of $2.73 has brought about a positive sentiment when calculated over the last 20 days. The market has allocated a beta of 2.17 to the stock. With the beta been greater than one, this implies that the company shares are theoretically more volatile than the market, something that the traders definitely are keeping an eye on.
Most of the analysts surveyed by Thomson/First Call think quite highly of ImmunoGen, Inc. — 2 analysts rate the stock as a buy with another 0 rating it strong buy. There are 6 analysts who maintain a hold rating for the stock, with 1 giving it a sell rating. Analysts arrived at a 12-month price target of $3.28 on shares of ImmunoGen, Inc. (NASDAQ:IMGN), which corresponds to 2.38% downside potential than its current market price of $3.375 and implies potential despite the recent advance in the price. However, their current target price has fallen from $3.28 a month ago and is up handily from the consensus target of $3.03 a quarter ago.
In the last five years, the EPS of the company has been roughly -7.6%. Though the percentage looks disappointing, extra headwinds are emerging as looking out over a next 5-year period, with analysts estimating that their earnings will decrease annually by 0%. The revenue of the company has retreated at an average annualized rate of about -2.3 over the last five years. The company recently recorded an increase of 66.7%, but this figure is rather attractive.
Let’s briefly check the hedge fund interest towards IMGN stock. Tower Research Capital LLC TRC changed position in the company and now owns 33,378 shares worth $112,651, SEC documents show. Alps Advisors Inc. cut assets in the stock as 312964.4 shares have been sold, reducing its stake by -4.5% to 298,881 shares which are currently valued at $1,008,723. In addition, SG Americas Securities LLC recently reported that it now owns 232,207 shares making a total of $783,699 based on the recent price. This refelects a change of 2175.9% in their ownership.